Browse News
Filter News
Found 538,969 articles
-
“This is Medidata’s first office in Boston, and the company is excited for the opportunity over the next several years to tap into the amazing life sciences and technology skills that Boston can offer,” said Medidata’s chief people officer.
-
A rap video extolling the virtues of prescribing a powerful fentanyl-based pain killer to patients beyond what the drug was initially intended, is coming back to haunt Insys founder John Kapoor.
-
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
-
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
If the new funding bill is signed by the president, the FDA will have some extra funds to support various initiatives.
-
With 5 Gene Therapies Licensed From Penn, Passage Bio Launches With $115.5 Million Series A
2/15/2019
Philadelphia-based Passage Bio launched with a Series A financing round worth $115.5 million. It was led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures. -
WHO Plans to Develop Oversight Standards for Gene Editing Following Chinese Researcher’s Experiment
2/15/2019
Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action. -
February 15 Research Roundup: Rare Pediatric Cancer, Hibernating Hamsters, Prostate Cancer and More
2/15/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Perhaps you sense something just isn’t quite right, but you’re not sure what. Or, maybe you have a pretty good idea that your organization is slimming down and your role will be one of the first ones to go.
-
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
-
Senseonics Announces Partnership with Geo-Med to Provide Veterans Access to Eversense CGM
2/15/2019
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that it has partnered with Geo-Med, LLC,
-
CBS News Interviews Dr. Ashraf Hanna and Patient About Ketamine Treatments for Patients at High Suicide Risk and Depression
2/15/2019
From 1999 to 2016, the rate of suicides in the U.S. increased by 30 percent. It's now the second-leading cause of death for 10 to 34-year-olds. Social media bullying, increasing economic disparity, returning veterans traumatized by war, and unintended consequences of the opioid crisis have all been cited as reasons for the rise in America.
-
Two Thousand NuLids® Systems Sold
2/15/2019
Dr. Crystal Brimer, founder of the Dry Eye Institute and owner of Focus Eye Care, Wilmington, NC, is the purchaser of the 2,000th NuLids System sold. NuLids, an innovative doctor-directed, home-use therapy in the fight against dry eye, effectively alleviates symptoms by stimulating and rejuvenating the Meibomian Glands back to a healthier state.
-
Dogwood Health Trust Hires Renowned Search Firm Witt/Kieffer to Recruit Organization's First CEO
2/15/2019
Dogwood Health Trust, a private, non-operating foundation whose purpose is to dramatically improve the health and well-being of all residents of Western North Carolina, has hired Witt/Kieffer, one of the world's foremost recruitment firms in the healthcare and not-for-profit sectors, to assist the Dogwood Health Trust Board of Directors and its search committee in selecting the organization's first chief executive officer.
-
Medical leaders back clinical utility of sphingotec's blood biomarker bio-ADM®
2/15/2019
German diagnostics company sphingotec GmbH (Hennigsdorf) reports that key opinion leaders have confirmed clinical utility of bio-ADM® (biologically active adrenomedullin), the company's proprietary marker for vascular leakage (endothelial dysfunction), in patients with congestion in heart failure and in patients with severe sepsis.
-
Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019
2/15/2019
Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of preliminary data from its Phase 2 trial of vofatamab, a fibroblast-growth-factor-receptor 3 (FGFR3) targeted antibody, at the 2019 ASCO Genitourinary Cancers Symposium in San Francisco.
-
Teckro raises $25 million Series C round to speed up clinical trials to fight world’s most complex diseases
2/15/2019
Teckro has raised a fresh round of funding to accelerate its aim of helping to bring drugs and treatments to market quicker and more efficiently.
-
Patient Groups Provide Educational Cannabis Content to Arizona Voters
2/15/2019
The American Council for Patient Liberty created a website and produced an educational video to inform Arizonans and elected officials about voter protected medical marijuana as well as hemp extracts in Arizona.
-
Statement from FDA Commissioner Scott Gottlieb, M.D., on new policy to improve access and foster price competition for drugs that face inadequate generic competition
2/15/2019
In too many cases, branded drugs that are no longer protected by patents or other exclusivities do not face expected competition. In fact, there are several hundred of such branded drugs that do not have any generic competition.